Cellogen Therapeutics Pvt. Ltd.

Based in India, Cellogen Therapeutics Pvt. Ltd. focuses on developing innovative cellular therapies, including advanced CAR T-cell therapies and gene manipulation techniques targeting hematological malignancies and blood disorders. Cellogen Therapeutics Pvt.

Ltd. was founded in 2021 and is headquartered in Noida, India. The company specializes in cellular therapeutics aimed at treating blood-related conditions. In May 2026, Cellogen raised INR 200 million from Kotak Alternate Asset Managers to further its CAR T-cell and gene therapy initiatives.

The company has engaged in one deal to date, signaling a commitment to expanding its market presence. Cellogen Therapeutics specializes in the development of innovative cellular therapies, particularly in the areas of CAR T-cell therapies and gene manipulation techniques. Their core offerings include advanced third and fourth generation CAR T-cell therapies designed to target hematological malignancies, such as leukemia and lymphoma, by bi-targeting antigens CD19 and CD20. Additionally, the company is pioneering gene-editing solutions for blood disorders, specifically beta-thalassemia and sickle cell disease, utilizing techniques like CRISPR to address the root causes of these conditions.

The primary end users of these therapies are cancer patients and individuals suffering from blood disorders, with a focus on providing affordable and accessible treatment options primarily in the Indian market, while also aiming to expand to other regions as clinical trials progress. Revenue generation at Cellogen Therapeutics is structured around partnerships with healthcare providers and research institutions that facilitate the clinical application of their therapies. Transactions typically occur through B2B collaborations, where hospitals and treatment centers acquire their CAR T-cell therapies and gene manipulation technologies for use in patient care. The company employs a pricing model that reflects the complexity and innovation inherent in their products, with revenue stemming from direct sales of therapies as well as potential licensing agreements for their proprietary technologies.

The flagship products within their portfolio, such as the bi-specific CAR T-cell therapies, are positioned to capture interest from healthcare providers seeking advanced treatment modalities, thereby contributing to the company's financial health through strategic partnerships and clinical applications. In May 2026, Cellogen Therapeutics Pvt. Ltd. raised INR 200 million in venture funding from Kotak Alternate Asset Managers.

The company plans to use this funding to advance its CAR T-cell programs, expand its gene therapy offerings, and enhance manufacturing and compliance processes. Looking ahead, Cellogen aims to introduce new products targeting additional hematological malignancies and blood disorders, with plans to enter new markets in Asia and Europe by the end of 2027 as part of their growth strategy.